Document is current

Article History

Received: 26 June 2024

Accepted: 9 October 2024

First Online: 19 October 2024

Declarations

:

: This project was reviewed and approved by New England Independent Review Board (Needham Heights, MA, United States; Work Oder# 1–1502098-1). It was determined by the Independent Review Board that this analysis was exempt due to deidentification of data and consent was not required per title 45 Code of Federal Regulations part 46.104(d)(4) in the United States. The analysis adhered to the Declaration of Helsinki.

: Not applicable.

: J.W.L., S.L., S.C., J.W., A.C.W., Y.J., M.S.G., L.A.U., J.L.H., F.W.M. report being an employee of Fresenius Medical Care. J.W.L., S.C., M.S.G., L.A.U., J.L.H., F.W.M. report having share options/ownership in Fresenius Medical Care. J.W.L., S.C., L.A.U., J.L.H., F.W.M. report being an inventor on patent(s) in the field of dialysis. J.W.L. reports receipt of honorarium from The Lancet, being on the Editorial Board of Frontiers in Physiology and Frontiers in Medicine, Nephrology, and being chairperson for a MONitoring Dialysis Outcomes (MONDO) Initiative study group and serve on the MONDO Steering Committee. L.A.U. reports being an advisory board member for Privacy Analytics Inc. F.W.M. reports directorships in Fresenius Medical Care Management Board and Vifor Fresenius Medical Care Renal Pharma. D.C.W. reports consultancy or honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, Galderma, GlaxoSmithKline, Eledon, Janssen, Mundipharma, Merk, Sharp and Dohme, ProKidney, Tricida, Vifor Fresenius Medical Care Renal Pharma, and Zydus. P.S. reports serving on scientific advisory boards or speaker honoraria for AstraZeneca, REATA, Vifor, Baxter Healthcare, GSK, Pfizer, Invizius, Astellas, Novo Nordisk, and Fresenius Medical Care. J.F. reports consultancy or speaker honoraria from AstraZeneca, Bayer, Boehringer, Fresenius Medical Care, and CSL Vifor.